- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01675973
A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine
December 4, 2012 updated by: Gilead Sciences
A Phase 1, Parallel-group, Open-label, Multiple-dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Ranolazine ER in Subjects With Severe Renal Impairment as Compared to Healthy Subjects With Normal Renal Function
The purpose of this study is to assess the effect of severe renal impairment on the steady-state PK, as well as safety and tolerability, of ranolazine, compared to subjects with normal renal function.
Study Overview
Detailed Description
The primary objective of this study is to assess the effects of severe renal impairment (RI) on the steady-state pharmacokinetics (PK) of ranolazine and key metabolites.
The secondary objective of this study is to assess the safety and tolerability of multiple oral doses of ranolazine in subjects with severe RI.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014
- Clinical Pharmacology of Miami
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria (All Cohorts):
- Males and females, 18 to 75 years old, inclusive
- Body mass index (BMI) 18 to 40 kg/m2, inclusive, at Screening
- Females of child-bearing potential must have a negative pregnancy test at Screening and on Day -1 (Cohort A) or Day -6 (Cohort B) and must agree to use highly effective contraception methods from Screening throughout the duration of the Treatment Period and for 14 days following the last dose of study drug
Inclusion criteria (Cohort A [Healthy subjects with normal renal function] only):
- Estimated creatinine clearance (CLCR), according to the Cockcroft-Gault (C-G) equation, ≥ 90 mL/min at Screening
- Age, BMI, and sex comparable to those of subjects of Cohort B
- Good health status as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
Inclusion criteria (Cohort B, Severe RI):
- Diagnosis of CKD
- Estimated glomerular filtration rate (eGFR), according to the Modification of Diet in Renal Disease (MDRD) equation, < 30 mL/min/1.73 m2 (and not receiving dialysis)
- Stable medication dose and dosing regimen for treatment of the complications of renal disease or other concomitant chronic illnesses for at least 2 weeks prior to study drug administration
Exclusion Criteria:
Exclusion criteria (All Cohorts):
- History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease
- Current or recent (within 3 months) gastrointestinal (GI) disease or any GI surgery that could impact absorption of study drug
- Any major surgery within 4 weeks of dosing with study drug
- Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 4 weeks of dosing with study drug
- Blood transfusion within 4 weeks of dosing with study drug
- Consumption of > 14 alcoholic drinks per week, or more than 4 alcoholic drinks on any one day
- History of regular use of tobacco- or nicotine-containing products in excess of 10 cigarettes per day or equivalent
- History of substance abuse within 12 months prior to Screening
- Positive drug screen
- Positive alcohol test
- Clinically significant history of hepatic disease
- QTcF interval > 480 msec at Screening or Day -6 (for Cohort B) or Day -1 (for Cohort A)
- History of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia, or torsade de pointes
- Known hypersensitivity or previous intolerance to ranolazine or any of its excipients
- Treatment with selected medications
- Pregnancy or lactation
- Other condition(s) that, in the opinion of the Investigator, would prevent compliance with the study protocol
Exclusion criteria (Cohort A [Healthy subjects with normal renal function] only):
- Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations
- Hemoglobin < 12 g/dL for males, < 11 g/dL for females at Screening
- Any prescription and over-the-counter medications, including herbal products
Exclusion criteria (Cohort B, Severe RI):
- Any clinical, ECG, and laboratory findings beyond those which are consistent with the degree of renal dysfunction
- History of or anticipated near-term need for renal transplant (within 3 months)
- History of hemodialysis or peritoneal dialysis within 1 year prior to Screening, or anticipated need for hemodialysis or peritoneal dialysis during the study
- History of acute renal failure or nephrotic syndrome within 1 year prior to Screening
- History of diabetic ketoacidosis
- History of severe hypoglycemia
- Other condition(s) that, in the opinion of the Investigator, would prevent compliance with the study protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Subjects with severe renal impairment
Cohort B (subjects with severe RI): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
|
500mg BID up to 1000mg BID
|
Experimental: Subjects with normal renal function
Cohort A (healthy subjects with normal renal function): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
|
500mg BID up to 1000mg BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration vs time curve over the dosing interval at steady state (AUCtau) and Maximum observed plasma concentration at steady-state (Cmax)
Time Frame: Day 7 for Cohorts A & B, and Day -1 for Cohort B only.
|
|
Day 7 for Cohorts A & B, and Day -1 for Cohort B only.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with AEs
Time Frame: From Day -5 for Cohort B or Day 1 for Cohort A through the 14-day follow-up.
|
From Day -5 for Cohort B or Day 1 for Cohort A through the 14-day follow-up.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
July 26, 2012
First Submitted That Met QC Criteria
August 29, 2012
First Posted (Estimate)
August 30, 2012
Study Record Updates
Last Update Posted (Estimate)
December 6, 2012
Last Update Submitted That Met QC Criteria
December 4, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GS-US-259-0112
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Renal Impairment
-
Kowa Research Institute, Inc.CompletedSevere Renal ImpairmentUnited States
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy Subjects | Severe Renal ImpairmentCzechia
-
Novartis PharmaceuticalsCompletedMild Moderate | or Severe Renal ImpairmentGermany
-
University of VermontMedical University of South Carolina; University of Washington; University of...Active, not recruitingEnd Stage Renal Disease | Severe Life-limiting COPD | Severe Life-limiting Heart Failure | Severe Life-limiting Cirrhosis | Severe Life-limiting Malignancy | Severe Functional ImpairmentUnited States
-
Ascelia Pharma ABCompletedSevere Renal Impairment | Known or Suspected Focal Liver LesionsUnited States, Italy, Germany, Poland, Russian Federation, Sweden, Turkey, Argentina, Colombia, Mexico
-
EQRx International, Inc.CompletedSevere Hepatic ImpairmentUnited States
-
PfizerCompleted
-
TakedaCompletedSevere Hepatic ImpairmentUnited States
-
Bausch Health Americas, Inc.TerminatedSevere Hepatic ImpairmentUnited States
-
Eisai Inc.CompletedHepatic Impairment; Renal ImpairmentUnited States
Clinical Trials on RANEXA
-
University of New MexicoGilead SciencesCompletedIschemia | Coronary Artery Disease | Myocardial Disease | Coronary MicrocirculationUnited States
-
Atlanta Heart Specialists, LLCGilead SciencesUnknownCoronary Artery Disease | Metabolic Syndrome | AnginaUnited States
-
University of California, San DiegoTerminatedDiastolic Heart Failure | Echocardiography | Ranolazine | Tissue Doppler UltrasoundUnited States
-
Cedars-Sinai Medical CenterUniversity of FloridaCompletedMicrovascular Coronary Dysfunction (MCD)United States
-
Ohio State UniversityGilead SciencesCompletedMyotonic Dystrophy 1 | Myotonia Congenita | Paramyotonia CongenitaUnited States
-
Amit Malhotra, MDGilead SciencesUnknown
-
Tel-Aviv Sourasky Medical CenterUnknownLong QT Syndrome Type 3Israel
-
Gilead SciencesThe TIMI Study GroupCompletedMyocardial IschemiaUnited States
-
University of OklahomaGilead SciencesTerminatedAtrial FibrillationUnited States
-
University Medical Centre LjubljanaCompletedDilated CardiomyopathySlovenia